Nanoparticles as tool for enhanced ophthalmic delivery of vancomycin: a multidistrict-based microbiological study, solid lipid nanoparticles formulation and evaluation

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorYousry C.
dc.contributor.authorFahmy R.H.
dc.contributor.authorEssam T.
dc.contributor.authorEl-laithy H.M.
dc.contributor.authorElkheshen S.A.
dc.contributor.otherDepartment of Pharmaceutics and Industrial Pharmacy
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherCairo University
dc.contributor.otherKasr El-Aini St
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Microbiology and Immunology
dc.contributor.otherand Biotechnology Center
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherCairo University
dc.contributor.otherKasr El-Aini St
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Pharmaceutics and Industrial Pharmacy
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherOctober University for Modern Sciences and Arts
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Pharmaceutical Technology
dc.contributor.otherFaculty of Pharmaceutical Sciences and Pharmaceutical Industries
dc.contributor.otherFuture University in Egypt
dc.contributor.otherCairo
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:41:33Z
dc.date.available2020-01-09T20:41:33Z
dc.date.issued2016
dc.descriptionScopus
dc.description.abstractContext: A microbiological multidistrict-based survey from different Egyptian governorates was conducted to determine the most prevalent causative agents of ocular infections in the Egyptian population. Antibiotic sensitivity testing was then performed to identify the most potent antimicrobial agent. Vancomycin (VCM) proved the highest activity against gram-positive Staphylococcus bacteria, which are the most commonly isolated causative agents of ocular infection. However, topically applied VCM suffers from poor ocular bioavailability because of its high molecular weight and hydrophilicity. Objective: The aim of the present study was to develop VCM-loaded solid lipid nanoparticles (SLNs) using water-in-oil-in-water (W/O/W) double emulsion, solvent evaporation technique to enhance ocular penetration and prolong ophthalmic residence of VCM. Method: Two consecutive full factorial designs (24 followed by 32) were adopted to study the effect of different formulation and process parameters on SLN formulation. The lipid type and structure, polyvinyl alcohol (PVA) molecular weight and concentration, sonication time, as well as lipid:drug ratio were studied as independent variables. The formulated SLN formulae were evaluated for encapsulation efficiency (EE%), particle size (PS), and zeta potential as dependent variables. Results: The statistically-optimized SLN formula (1:1 ratio of glyceryltripalmitate:VCM with 1% low molecular weight PVA and 1 min sonication time) had average PS of 277.25 nm, zeta potential of ?20.45, and 19.99% drug encapsulation. Scanning and transmission electron micrographs showed well-defined, spherical, homogenously distributed particles. Conclusion: The present study suggests that VCM incorporation into SLNs is successfully achievable; however, further studies with different nanoencapsulation materials and techniques would be valuable for improving VCM encapsulation. � 2016 Informa UK Limited, trading as Taylor & Francis Group.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=21190&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.3109/03639045.2016.1171335
dc.identifier.doiPubMed ID 27093938
dc.identifier.issn3639045
dc.identifier.otherhttps://doi.org/10.3109/03639045.2016.1171335
dc.identifier.otherPubMed ID 27093938
dc.identifier.urihttps://t.ly/mb8vr
dc.language.isoEnglishen_US
dc.publisherTaylor and Francis Ltd.en_US
dc.relation.ispartofseriesDrug Development and Industrial Pharmacy
dc.relation.ispartofseries42
dc.subjectEgypten_US
dc.subjectmulti-district microbiological surveyen_US
dc.subjectocular infectionen_US
dc.subjectsolid lipid nanoparticlesen_US
dc.subjectvancomycinen_US
dc.subjectamikacinen_US
dc.subjectamoxicillinen_US
dc.subjectamoxicillin plus clavulanic aciden_US
dc.subjectampicillinen_US
dc.subjectazithromycinen_US
dc.subjectaztreonamen_US
dc.subjectcefoperazoneen_US
dc.subjectcefoperazone plus sulbactamen_US
dc.subjectcefotaximeen_US
dc.subjectciprofloxacinen_US
dc.subjectclarithromycinen_US
dc.subjectcotrimoxazoleen_US
dc.subjectgelucireen_US
dc.subjectgentamicinen_US
dc.subjectguanosine diphosphateen_US
dc.subjectguanosine phosphateen_US
dc.subjectimipenemen_US
dc.subjectlevofloxacinen_US
dc.subjectmeticillinen_US
dc.subjectmezlocillinen_US
dc.subjectnovobiocinen_US
dc.subjectoilen_US
dc.subjectpiperacillinen_US
dc.subjectpolyvinyl alcoholen_US
dc.subjectsolid lipid nanoparticleen_US
dc.subjectsultamicillinen_US
dc.subjecttripalmitinen_US
dc.subjectvancomycinen_US
dc.subjectwateren_US
dc.subjectemulsionen_US
dc.subjectlipiden_US
dc.subjectnanoparticleen_US
dc.subjectvancomycinen_US
dc.subjectantibiotic sensitivityen_US
dc.subjectArticleen_US
dc.subjectdrug formulationen_US
dc.subjectdrug penetrationen_US
dc.subjectevaporationen_US
dc.subjectintraocular drug administrationen_US
dc.subjectminimum inhibitory concentrationen_US
dc.subjectmolecular weighten_US
dc.subjectnanoencapsulationen_US
dc.subjectnanopharmaceuticsen_US
dc.subjectnonhumanen_US
dc.subjectparticle sizeen_US
dc.subjectStaphylococcusen_US
dc.subjectzeta potentialen_US
dc.subjectchemical phenomenaen_US
dc.subjectchemistryen_US
dc.subjectdrug delivery systemen_US
dc.subjectemulsionen_US
dc.subjecteyeen_US
dc.subjectmicrobiological phenomena and functionsen_US
dc.subjectmicrobiologyen_US
dc.subjectproceduresen_US
dc.subjectultrasounden_US
dc.subjectDrug Delivery Systemsen_US
dc.subjectEmulsionsen_US
dc.subjectEyeen_US
dc.subjectHydrophobic and Hydrophilic Interactionsen_US
dc.subjectLipidsen_US
dc.subjectMicrobiological Phenomenaen_US
dc.subjectNanoparticlesen_US
dc.subjectParticle Sizeen_US
dc.subjectPolyvinyl Alcoholen_US
dc.subjectSonicationen_US
dc.subjectVancomycinen_US
dc.titleNanoparticles as tool for enhanced ophthalmic delivery of vancomycin: a multidistrict-based microbiological study, solid lipid nanoparticles formulation and evaluationen_US
dc.typeArticleen_US
dcterms.isReferencedByWilhelmus, K.R., Liesegang, T.J., Osato, M.S., Jones, D.B., (1994) Cumitech 13A, Laboratory diagnosis of ocular infections, pp. 9-20. , Washington, DC: American Society for Microbiology; Southwick, F.S., Eye, ear, nose, and throat infections (2014) Infectious diseases a clinical short course, pp. 125-132. , Southwick F., (ed), 3rd edn., New York: McGraw-Hill Education; Schaefer, F., Bruttin, O., Zografos, L., Guex-Crosier, Y., Bacterial keratitis: a prospective clinical and microbiological study (2001) Br J Ophthalmol, 85, pp. 842-847; Cheung, R.P.F., Dipiro, J.T., Vancomycin: an update (1986) Pharmacotherapy, 6, pp. 153-169; Mohammed Fayaz, A., Girilal, M., Mahdy, S.A., Vancomycin bound biogenic gold nanoparticles: a different perspective for development of anti VRSA agents (2011) Process Biochem, 46, pp. 636-641; Moffat, A.C., Osselton, M.D., Widdop, B., (2005) Clarke's analysis of drugs and poisons, , London, UK: Pharmaceutical Press; Vila, M.M.D.C., Oliveira, R.M.D., Gon�alves, M.M., Tubino, M., Analytical methods for vancomycin determination in biological fluids and in pharmaceuticals (2007) Quim Nov, 30, pp. 395-399; Gavini, E., Chetoni, P., Cossu, M., PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies (2004) Eur J Pharm Biopharm, 57, pp. 207-212; Hachicha, W., Kodjikian, L., Fessi, H., Preparation of vancomycin microparticles: importance of preparation parameters (2006) Int J Pharm, 324, pp. 176-184; Ara�jo, J., Gonzalez, E., Egea, M.A., Nanomedicines for ocular NSAIDs: safety on drug delivery (2009) Nanomedicine, 5, pp. 394-401; Kaur, I.P., Garg, A., Singla, A.K., Aggarwal, D., Vesicular systems in ocular drug delivery: an overview (2004) Int J Pharm, 269, pp. 1-14; Liu, G.Y., Omri, A., Sande, L., (2011), http://www.google.com/patents/WO2012149116A2?cl=en; Attama, A., Reichl, S., M�ller-Goymann, C.C., Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct (2008) Int J Pharm, 355, pp. 307-313; Ghadiri, M., Fatemi, S., Vatanara, A., Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size (2012) Int J Pharm, 424, pp. 128-137; Hansraj, G.P., Singh, S.K., Kumar, P., Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential (2015) Int J Biol Macromol, 81, pp. 467-476; Shah, B., Khunt, D., Bhatt, H., Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters (2015) Eur J Pharm Sci, 78, pp. 54-66; Jeong, Y.-I., Na, H.-S., Seo, D.-H., Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity (2008) Int J Pharm, 352, pp. 317-323; Wissing, S.A., Kayser, O., M�ller, R.H., Solid lipid nanoparticles for parenteral drug delivery (2004) Adv Drug Deliv Rev, 56, pp. 1257-1272; Nabi-meibodi, M., Vatanara, A., Rouholamini, A., The effective encapsulation of a hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent evaporation method (2013) Colloids Surf B Biointerfaces, 112, pp. 408-414; Performance standards for antimicrobial susceptibility testing (2009) 19th Informational Suppl CLSI Doc M100-S19. Wayne, PA: CLSI;; Ismail, M.M., Essam, T.M., Mohamed, A.F., Mourad, F.E., Screening for the antimicrobial activities of alcoholic and aqueous extracts of some common species in Egypt (2012) Int J Microbiol Res, 3, pp. 200-207; Performance standards for antimicrobial susceptibility testing (2011) 21st Informational Suppl CLSI Doc M100-S21. Wayne, PA: CLSI;; Hou, D., Xie, C., Huang, K., Zhu, C., The production and characteristics of solid lipid nanoparticles (SLNs) (2003) Biomaterials, 24, pp. 1781-1785; Aksoy, D.Y., Tanriover, M.D., Unal, S., Antimicrobial resistance: preventable or inevitable (2008) Antibiotic policies: fighting resistance, pp. 113-134. , Gould I.M., Meer J.W.V.D., (eds), New York: Springer Science + Business Media, LLC; Aksungur, P., Demirbilek, M., Denkbas, E.B., Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies (2011) J Control Release, 151, pp. 286-294; Mehnert, W., Mader, K., Solid lipid nanoparticles: production, characterization and applications (2001) Adv Drug Deliv Rev, 47, pp. 165-196; Westesen, K., Michel, H.J., Crystallization tendency and polymorphic transitions in triglyceride nanoparticles (1996) Int J Pharm, 129, pp. 159-173; Abdelbary, G., Fahmy, R.H., Diazepam-loaded solid lipid nanoparticles: design and characterization (2009) AAPS PharmSciTech, 10, pp. 211-219; Manosroi, A., Wongtrakul, P., Manosroi, J., Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol (2003) Colloids Surf B Biointerfaces, 30, pp. 129-138; Chibowski, S., Paszkiewicz, M., Krupa, M., Investigation of the influence of the polyvinyl alcohol adsorption on the electrical properties of Al2O3 � solution interface, thickness of the adsorption layers of PVA (2000) Powder Technol, 107, pp. 251-255; Mobarak, D.H., Salah, S., Elkheshen, S.A., Formulation of ciprofloxacin hydrochloride loaded biodegradable nanoparticles: optimization of technique and process variables (2013) Pharm Dev Technol, 19, pp. 891-900; M�ller, R.H., Vuleta, G.M., Kov?, A.B., Keck, C.M., Physicochemical and engineering aspects solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: preparation, characterization and physical stability investigation (2014) Colloids Surf A Physicochem Eng Asp, 444, pp. 15-25; Uner, M., Yener, G., Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives (2007) Int J Nanomedicine, 2, pp. 289-300; Guinedi, A.S., Mortada, N.D., Mansour, S., Hathout, R.M., Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide (2005) Int J Pharm, 306, pp. 71-82; Jenning, V., Gohla, S., Comparison of wax and glyceride solid lipid nanoparticles (SLN) (2000) Int J Pharm, 196, pp. 219-222; M�ller, R.H., M�der, K., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery � a review of the state of the art (2000) Eur J Pharm Biopharm, 50, pp. 161-177; Moosa, R.M., Choonara, Y.E., Toit, L.C.D., In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model (2014) Int J Pharm, 466, pp. 296-306; Zakeri-milani, P., Loveymi, B.D., Jelvehgari, M., The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system (2013) Colloids Surf B Biointerfaces, 103, pp. 174-181; Vitorino, C., Carvalho, F.A., Almeida, A.J., Sousa, J.J., The size of solid lipid nanoparticles: an interpretation from experimental design (2011) Colloids Surf B Biointerfaces, 84, pp. 117-130; Gupta, H., Pharm, B., Pharm, M., Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery (2010) Nanomedicine, 6, pp. 324-333
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
avatar_scholar_128.png
Size:
2.73 KB
Format:
Portable Network Graphics
Description:
Download

Collections

Faculty Of Pharmacy Research Paper